샘플 요청 목록

 카트 문의
시장보고서
상품코드
1813950

기도양압 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Positive Airway Pressure Devices Market Size, Share & Trends Analysis Report By Product (CPAP, APAP, BiPAP), By Application (OSA, COPD), By End Use (Home Care Settings, Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

기도양압 기기 시장 요약

세계 기도양압 기기 시장 규모는 2024년 24억 8,000만 달러로 추정되며, 2033년에는 40억 4,000만 달러에 달할 것으로 예상되며, 2025년부터 2033년까지 5.60%의 CAGR로 성장할 것으로 예상됩니다.

이러한 성장의 배경에는 수면무호흡증 유병률 증가, 기술 발전, 수면장애에 대한 인식과 진단의 증가, 의료 인프라의 개선 등이 있습니다.

이러한 요인들은 전 세계적으로 PAP 기기에 대한 수요를 촉진하고 있습니다. 건강에 대한 관심 증가, 더 나은 진단 방법, 기술 혁신이 시장의 미래 성장 전망을 형성하고 있습니다. 폐쇄성 수면무호흡증후군은 환자가 불규칙한 호흡 패턴에 직면하여 뇌에 산소 공급이 감소하는 호흡기질환입니다. 2023년 Saudi Journal of Otorhinolaryngology-Head and Neck Surgery가 발표한 폐쇄성 수면무호흡증 유병률에 대한 전 세계 추정치에 따르면, 약 9억 3,600만 명이 경증에서 중증 수면무호흡증으로 고통 받고 있으며 이 중 30-69세의 4억 2,500만 명이 중등도에서 중증의 수면무호흡증후군을 앓고 있습니다. 급속한 세계화, 라이프스타일의 변화, 건강에 해로운 식습관 등은 수면무호흡증 확산에 기여하는 몇 가지 요인입니다. 또한, 비만율 증가와 운동 부족으로 인해 폐쇄성 수면무호흡증 발병률이 증가하고 있습니다.

수면장애에 대한 인식과 진단의 증가는 시장 성장을 촉진하는 중요한 요인입니다. 사람들이 수면무호흡증과 그 잠재적 위험에 대해 더 많이 알게 됨에 따라 진단과 치료를 받을 가능성이 높아지고 있습니다. 미국수면무호흡증협회(American Sleep Apnea Association)와 같은 단체에서 진행하는 공중보건 캠페인은 인식 개선에 큰 도움이 되고 있습니다. 또한 수면다원검사, 재택수면검사 등 진단방법의 개선으로 수면무호흡증후군의 조기발견이 쉬워졌습니다. 수면무호흡증이 심각한 건강 문제라는 인식이 높아짐에 따라 PAP 치료를 받는 사람들이 늘어나면서 시장 수요에 박차를 가하고 있습니다.

COVID-19 전염병은 PAP 기기 시장에 긍정적인 영향을 미쳤습니다. 2022년 National Centre for Biotechnology Information에서 발표한 연구에 따르면, 재택 CPAP로 치료한 폐쇄성 수면무호흡증은 COVID-19 입원 환자의 예후 악화와 관련이 없으며, CPAP는 팬데믹 기간 동안에도 안전하게 지속될 수 있다는 연구 결과가 발표되었습니다. 할 수 있음을 시사했습니다. 원격의료 서비스는 CPAP의 순응도를 향상시키고, 환자가 더 나은 원격 지원을 받을 수 있게 되었기 때문에 록다운 기간 동안 사용량이 증가했다는 보고도 있습니다. 팬데믹은 수면 장애를 관리하고 중증 환자의 호흡기 건강을 유지하는 데 있어 PAP 기기의 중요성을 부각시켰습니다.

또한, 2024년 6월 30일로 끝나는 회계연도 연례보고서에 따르면, COVID-19 사태는 회사의 매출, 특히 수면 및 호흡기 관리 부문에 영향을 미쳤습니다. 보고서에 따르면, 팬데믹 기간 동안 호흡기 건강에 대한 인식이 높아지면서 레스메드의 PAP 기기에 대한 수요가 증가했다고 합니다. 이러한 수요 급증은 COVID-19와 관련된 호흡기질환을 앓고 있는 환자들을 위한 실용적이고 비침습적인 환기 옵션에 대한 필요성에 의해 발생했습니다. 수면무호흡증 및 COVID-19 관련 호흡기 합병증 관리의 중요한 역할을 반영하여 ResMed와 같은 시장 기업들은 PAP 기기 매출이 크게 증가했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 기도양압 기기 시장 변수, 동향 및 범위

  • 시장 계통 전망
    • 상부 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
    • 시장 기회 분석
    • 시장 과제 분석
  • 양압호흡 디바이스 시장 분석 툴
    • 업계 분석 - Porter's Five Forces 분석
    • PESTEL 분석
  • 규제 개요
  • 테크놀러지 개요(현재 제품과 차세대 기능)
  • 기도양압 기기의 주요 거래 및 전략적 제휴 분석
  • COVID-19의 영향

제4장 기도양압 기기 시장 : 제품 추정·동향 분석

  • 정의와 범위
  • 제품 시장 점유율 분석, 2024년 및 2033년
  • 부문 대시보드
  • 기도양압 기기 시장 : 제품별, 2021-2033년
    • CPAP
    • APAP
    • BiPAP

제5장 기도양압 기기 시장 : 용도 추정·동향 분석

  • 정의와 범위
  • 용도 시장 점유율 분석, 2024년 및 2033년
  • 부문 대시보드
  • 기도양압 기기 시장 : 용도별, 2021-2033년
    • 폐쇄성 수면무호흡증
    • 호흡부전
    • COPD

제6장 기도양압 기기 시장 : 최종 용도 추정·동향 분석

  • 정의와 범위
  • 최종 용도 시장 점유율 분석, 2024년 및 2033년
  • 부문 대시보드
  • 기도양압 기기 시장 : 최종 용도별, 2021-2033년
    • 병원과 진료소
    • 재택 케어 설정
    • 기타(요양시설 등)

제7장 기도양압 기기 시장 : 지역별, 제품별, 용도별, 최종 용도별 지역 추정·동향 분석

  • 지역 대시보드
  • 시장 규모와 예측 동향 분석, 2021년에서 2033년 :
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 한국
    • 태국
    • 호주
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제8장 경쟁 구도

  • 참여자 개요
  • 기업 시장 상황 분석, 2024년
  • CPAP 기기 기업 시장 점유율 분석(2024년)
  • 기업 시장 점유율 분석, APAP 디바이스, 2024년
  • 기업 시장 점유율 분석, Bi-PAP 디바이스, 2024년
  • 기업 분류
  • 기업 개요/상장 기업
    • Koninklijke Philips NV
    • Fisher &Paykel Healthcare Limited
    • ResMed
    • Drive DeVilbiss Healthcare
    • React Health(3B Medical)
    • BMC Medical
    • Armstrong Medical Inc.
    • Wellell(Apex Medical)
    • Breas Medical
    • SEFAM
    • Trudell Medical(Vyaire)
    • Lowenstein Medical UK Ltd
    • Transcend Inc.(Somnetics International, Inc.)
KSM 25.09.26

Positive Airway Pressure Devices Market Summary

The global positive airway pressure devices market size was estimated at USD 2.48 billion in 2024 and is projected to reach USD 4.04 billion by 2033, growing at a CAGR of 5.60% from 2025 to 2033. This growth is attributed to the increasing prevalence of sleep apnea, advancements in technology, rising awareness and diagnosis of sleep disorders, and improving healthcare infrastructure.

These factors are fueling the demand for PAP devices globally. Growing health concerns, better diagnostic methods, and technological innovations are shaping the market's future growth prospects. Obstructive sleep apnea is a respiratory disorder wherein the patient faces irregular breathing patterns with reduced oxygen supply to the brain. According to the Saudi Journal of Otorhinolaryngology-Head and Neck Surgery estimates on the global prevalence of obstructive sleep apnea published in 2023, approximately 936 million people are suffering from mild to severe sleep apnea, and among these, 425 million individuals in the age group of 30 to 69 years are suffering from moderate-to-severe sleep apnea. Rapid globalization, changing lifestyles, and unhealthy dietary habits are a few factors contributing to the prevalence of sleep apnea. In addition, growing obesity levels and a lack of physical activity are driving the incidence rate of obstructive sleep apnea.

Rising awareness and diagnosis of sleep disorders are crucial factors propelling market growth. As people become more educated about sleep apnea and its potential risks, they are more likely to seek diagnosis and treatment. Public health campaigns run by organizations such as the American Sleep Apnea Association have helped improve awareness. In addition, improved diagnostic methods such as polysomnography and home sleep tests have made identifying sleep apnea in its early stages easier. The increasing recognition of sleep apnea as a significant health concern drives more individuals to pursue PAP therapy, thus fueling market demand.

The COVID-19 pandemic had a positive impact on the PAP devices market. According to a study published by the National Centre for Biotechnology Information in 2022, obstructive sleep apnea treated with home CPAP was not associated with worse outcomes in hospitalized COVID-19 patients, suggesting that CPAP can be safely continued during the pandemic. Telehealth services improved CPAP adherence, with some reports showing increased usage during lockdowns as patients received better remote support. The pandemic has highlighted the importance of PAP devices in managing sleep disorders and supporting respiratory health in critically ill patients.

Furthermore, according to ResMed's annual report for the fiscal year ending June 30, 2024, the COVID-19 pandemic impacted the company's sales, particularly in its sleep and respiratory care segment. The report indicates an increased demand for ResMed's PAP devices due to the heightened awareness of respiratory health during the pandemic. This surge in demand was driven by the need for practical, non-invasive ventilation options for patients with respiratory issues related to COVID-19. Market players such as ResMed experienced strong revenue growth in its PAP device sales, reflecting its critical role in managing sleep apnea and respiratory complications associated with COVID-19.

Global Positive Airway Pressure Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global positive airway pressure devices market report based on product, application, end use, and region:

  • Product Outlook (Volume, 000'Units; Revenue, USD Million, 2021 - 2033)
  • CPAP
  • APAP
  • BiPAP
  • Application Outlook (Volume, 000'Units; Revenue, USD Million, 2021 - 2033)
  • Obstructive Sleep Apnea
  • Respiratory Failures
  • COPD
  • End Use Outlook (Volume, 000'Units; Revenue, USD Million, 2021 - 2033)
  • Home Care Settings
  • Hospitals & Clinics
  • Others (Long-Term Care Facilities, etc.)
  • Regional Outlook (Volume, 000'Units; Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Details of primary research
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. Research Scope and Assumptions
    • 1.8.1. List of Secondary Sources
    • 1.8.2. List of Primary Sources
    • 1.8.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Application Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Positive Airway Pressure Devices Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Incidence of Obstructive Sleep Apnea (OSA)
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Supportive Initiatives by Government and Private Organizations for PAP Devices
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Product Recalls and Device Failures
      • 3.2.2.2. Patient discomfort and compliance issues
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. Positive Airway Pressure Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal Landscape
  • 3.4. Regulatory Overview
  • 3.5. Technology overview (current products vs. next-gen features)
  • 3.6. Major Deals & Strategic Alliances Analysis in the Positive Airway Pressure Devices
  • 3.7. COVID-19 Impact

Chapter 4. Positive Airway Pressure Devices Market: Product Estimates & Trend Analysis

  • 4.1. Definition and Scope
  • 4.2. Product Market Share Analysis, 2024 & 2033
  • 4.3. Segment Dashboard
  • 4.4. Positive Airway Pressure Devices Market: By Product, 2021 to 2033
    • 4.4.1. CPAP
      • 4.4.1.1. CPAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
    • 4.4.2. APAP
      • 4.4.2.1. APAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
    • 4.4.3. BiPAP
      • 4.4.3.1. BiPAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units

Chapter 5. Positive Airway Pressure Devices Market: Application Estimates & Trend Analysis

  • 5.1. Definition and Scope
  • 5.2. Application Market Share Analysis, 2024 & 2033
  • 5.3. Segment Dashboard
  • 5.4. Positive Airway Pressure Devices Market: By Application, 2021 to 2033
    • 5.4.1. Obstructive Sleep Apnea
      • 5.4.1.1. Obstructive Sleep Apnea Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
    • 5.4.2. Respiratory Failures
      • 5.4.2.1. Respiratory Failures Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
    • 5.4.3. COPD
      • 5.4.3.1. COPD Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units

Chapter 6. Positive Airway Pressure Devices Market: End Use Estimates & Trend Analysis

  • 6.1. Definition and Scope
  • 6.2. End Use Market Share Analysis, 2024 & 2033
  • 6.3. Segment Dashboard
  • 6.4. Positive Airway Pressure Devices Market: By End Use, 2021 to 2033
    • 6.4.1. Hospitals and Clinics
      • 6.4.1.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
    • 6.4.2. Home Care Settings
      • 6.4.2.1. Home Care Settings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
    • 6.4.3. Others (Long-Term Care Facilities, etc.)
      • 6.4.3.1. Others (Long-Term Care Facilities, etc.) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units

Chapter 7. Positive Airway Pressure Devices Market: Regional Estimates & Trend Analysis by Region, Product, Application, End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework
      • 7.3.1.3. Reimbursement Scenario
      • 7.3.1.4. Competitive scenario
      • 7.3.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework
      • 7.3.2.3. Reimbursement Scenario
      • 7.3.2.4. Competitive scenario
      • 7.3.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework
      • 7.3.3.3. Reimbursement Scenario
      • 7.3.3.4. Competitive scenario
      • 7.3.3.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework
      • 7.4.1.3. Reimbursement Scenario
      • 7.4.1.4. Competitive scenario
      • 7.4.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Reimbursement Scenario
      • 7.4.2.4. Competitive scenario
      • 7.4.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework
      • 7.4.3.3. Reimbursement Scenario
      • 7.4.3.4. Competitive scenario
      • 7.4.3.5. France market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework
      • 7.4.4.3. Reimbursement Scenario
      • 7.4.4.4. Competitive scenario
      • 7.4.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework
      • 7.4.5.3. Reimbursement Scenario
      • 7.4.5.4. Competitive scenario
      • 7.4.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.4.6. Denmark
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework
      • 7.4.6.3. Reimbursement Scenario
      • 7.4.6.4. Competitive scenario
      • 7.4.6.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework
      • 7.4.7.3. Reimbursement Scenario
      • 7.4.7.4. Competitive scenario
      • 7.4.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.4.8. Norway
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework
      • 7.4.8.3. Reimbursement Scenario
      • 7.4.8.4. Competitive scenario
      • 7.4.8.5. Norway market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework
      • 7.5.1.3. Reimbursement Scenario
      • 7.5.1.4. Competitive scenario
      • 7.5.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Reimbursement Scenario
      • 7.5.2.4. Competitive scenario
      • 7.5.2.5. China market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Reimbursement Scenario
      • 7.5.3.4. Competitive scenario
      • 7.5.3.5. India market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.5.4. South Korea
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Reimbursement Scenario
      • 7.5.4.4. Competitive scenario
      • 7.5.4.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.5.5. Thailand
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework
      • 7.5.5.3. Reimbursement Scenario
      • 7.5.5.4. Competitive scenario
      • 7.5.5.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.5.6. Australia
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework
      • 7.5.6.3. Reimbursement Scenario
      • 7.5.6.4. Competitive scenario
      • 7.5.6.5. Australia market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework
      • 7.6.1.3. Reimbursement Scenario
      • 7.6.1.4. Competitive scenario
      • 7.6.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Reimbursement Scenario
      • 7.6.2.4. Competitive scenario
      • 7.6.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework
      • 7.7.1.3. Reimbursement Scenario
      • 7.7.1.4. Competitive scenario
      • 7.7.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Reimbursement Scenario
      • 7.7.2.4. Competitive scenario
      • 7.7.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Reimbursement Scenario
      • 7.7.3.4. Competitive scenario
      • 7.7.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework
      • 7.7.4.3. Reimbursement Scenario
      • 7.7.4.4. Competitive scenario
      • 7.7.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million) (000') Units

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Company Market Share Analysis, CPAP Devices, 2024
  • 8.4. Company Market Share Analysis, APAP Devices, 2024
  • 8.5. Company Market Share Analysis, Bi-PAP Devices, 2024
  • 8.6. Company Categorization
  • 8.7. Company Profiles/Listing
    • 8.7.1. Koninklijke Philips N.V.
      • 8.7.1.1. Participant's Overview
      • 8.7.1.2. Financial Performance
      • 8.7.1.3. Product Benchmarking
      • 8.7.1.4. Strategy Mapping
    • 8.7.2. Fisher & Paykel Healthcare Limited
      • 8.7.2.1. Participant's Overview
      • 8.7.2.2. Financial Performance
      • 8.7.2.3. Product Benchmarking
      • 8.7.2.4. Strategy Mapping
    • 8.7.3. ResMed
      • 8.7.3.1. Participant's Overview
      • 8.7.3.2. Financial Performance
      • 8.7.3.3. Product Benchmarking
      • 8.7.3.4. Strategy Mapping
    • 8.7.4. Drive DeVilbiss Healthcare
      • 8.7.4.1. Participant's Overview
      • 8.7.4.2. Financial Performance
      • 8.7.4.3. Product Benchmarking
      • 8.7.4.4. Strategy Mapping
    • 8.7.5. React Health (3B Medical)
      • 8.7.5.1. Participant's Overview
      • 8.7.5.2. Financial Performance
      • 8.7.5.3. Product Benchmarking
      • 8.7.5.4. Strategy Mapping
    • 8.7.6. BMC Medical
      • 8.7.6.1. Participant's Overview
      • 8.7.6.2. Financial Performance
      • 8.7.6.3. Product Benchmarking
      • 8.7.6.4. Strategy Mapping
    • 8.7.7. Armstrong Medical Inc.
      • 8.7.7.1. Participant's Overview
      • 8.7.7.2. Financial Performance
      • 8.7.7.3. Product Benchmarking
      • 8.7.7.4. Strategy Mapping
    • 8.7.8. Wellell (Apex Medical)
      • 8.7.8.1. Participant's Overview
      • 8.7.8.2. Financial Performance
      • 8.7.8.3. Product Benchmarking
      • 8.7.8.4. Strategy Mapping
    • 8.7.9. Breas Medical
      • 8.7.9.1. Participant's Overview
      • 8.7.9.2. Financial Performance
      • 8.7.9.3. Product Benchmarking
      • 8.7.9.4. Strategy Mapping
    • 8.7.10. SEFAM
      • 8.7.10.1. Participant's Overview
      • 8.7.10.2. Financial Performance
      • 8.7.10.3. Product Benchmarking
      • 8.7.10.4. Strategy Mapping
    • 8.7.11. Trudell Medical (Vyaire)
      • 8.7.11.1. Participant's Overview
      • 8.7.11.2. Financial Performance
      • 8.7.11.3. Product Benchmarking
      • 8.7.11.4. Strategy Mapping
    • 8.7.12. Lowenstein Medical UK Ltd
      • 8.7.12.1. Participant's Overview
      • 8.7.12.2. Financial Performance
      • 8.7.12.3. Product Benchmarking
      • 8.7.12.4. Strategy Mapping
    • 8.7.13. Transcend Inc. (Somnetics International, Inc.)
      • 8.7.13.1. Participant's Overview
      • 8.7.13.2. Financial Performance
      • 8.7.13.3. Product Benchmarking
      • 8.7.13.4. Strategy Mapping
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제